17,261 trials
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Progression-free Survival (PFS) — 10.9; 10.1 months — p=0.3531
Hidradenitis Suppurativa
Primary: Change in Modified Sartorius Score — -34.8 units on a scale — p=0.024
Prostatic Neoplasms · Prostate Cancer
Primary: PSA Reduction ≥ 50% — 0 participants
Psoriasis
Primary: Number of Participants in Each Treatment Group With Clinical Cure: Physician's Global Assessment (PGA) Score = 0 or 1 at Day 28 — 13.33; 10.00; 20.69; 37.93 percentage…
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Local Regional Control Rate at 2 Years — 0.61; 0.68 proportion of paticipants
Ocular Hypertension · Primary Open-Angle Glaucoma
Primary: Part 1: Change From Baseline in Intraocular Pressure (IOP) — 25.4; 25.6; 24.3; 26.7 Millimeters of Mercury (mmHg)
Multiple Myeloma
Primary: Bone Mineral Density (BMD) — 0.14; -2.68 T-scores
Lung Cancer
Primary: Progression-free Survival — 5.5; 4.4 Months
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Alcohol Dependence
Primary: Percent Heavy Drinking Days — 3.8; 3.0 percentage of heavy drinking days
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Gastric Adenocarcinoma · Gastric Intestinal Type Adenocarcinoma
Primary: Overall Survival (OS) — 5 months
Diabetic Macular Edema
Primary: Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye — 27.8; 23.6 Percentage of Patients
Osteosarcoma · Malignant Fibrous Histiocytoma (MFH) of Bone
Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants
Diabetic Macular Edema · Vitrectomy
Primary: Change From Baseline in Central Retinal Thickness in the Study Eye — 403.4; -38.9 Microns
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects